Research programme: oral therapeutics - ChiasmaAlternative Names: CH 3; Chiasma Investigational Product 3; CHIP-3
Latest Information Update: 14 Oct 2015
At a glance
- Originator Chiasma
- Class Peptides; Proteins; Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 14 Oct 2015 Early research is ongoing in Israel
- 01 Jul 2012 Early research in Undefined indication in Israel (PO)